Main page content

Displaying results 1 - 6 of 6
Publication ID: PEP20-07-02-001
Published:

The National report presents indicators as measured through the 2019 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services. State reports provide a snapshot of substance use and mental health in the United States.

Publication ID: PEP20-03-03-013
Published:

Consejos para adolescentes: la realidad sobre los opioides

This fact sheet for teens provides facts about opioids. It describes short- and long-term effects, lists signs of use, and helps dispel common myths. It also can be used by prevention professionals, educators, health care providers, and others who come in contact with teens on a regular basis.

Publication ID: SMA19-Baro-17-US
Published:

The National report presents indicators as measured through the 2017 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services. State reports provide a snapshot of substance use and mental health in the United States.

Publication ID: SMA18-5092FLY
Published:

This flyer is related to the public service announcement from SAMHSA's "Talk. They Hear You." campaign encouraging parents to talk with their kids about opioids.

Publication ID: SMA17-BAROUS-16
Published:

This report presents national data about the prevalence of behavioral health conditions. This data includes the rate of serious mental illness, suicidal thoughts, substance use, and underage drinking. The report also highlights the percentages of those who seek treatment for these conditions. The state-level Barometers contain valuable insight into the behavioral health needs and the unique challenges faced by communities across the country. This analysis can help public health authorities and others determine the best ways of meeting behavioral health care needs and disparities among various communities.

Publication ID: SMA14-4852
Published:

This guide highlights the use of medication-assisted treatment (MAT) for opioid use disorder in drug courts. It reviews effective medications, including methadone, buprenorphine, and naltrexone. The guide also provides strategies to increase the use of MAT in drug court programs.